InvestSMART

Cardiex Limited (ASX:CDX)

ALERT: Price-sensitive ASX Announcement for CDX
Current share price for CDX : $0.036 0.005 (16.13%)+
Announcement
Release
29 Aug 2025 4:11PM
Price at Release
$0.031
Full Release
download
Summary
Cardiex Limited's Appendix 4E Preliminary Final Report for the financial year ending 30 June 2025 highlights significant financial challenges. The company reported a net loss of AUD 13.23 million, increased from the previous year's loss due to higher expenses and a significant decrease in revenue from the previous year's high of AUD 10.9 million to AUD 3.55 million in 2025. This decline was attributed to reduced customer receipts following the completion of a major clinical trial project in the prior period. Despite increased proceeds from share issues and financing activities totaling AUD 12.87 million, these were insufficient to offset the operational cash outflows and other expenses. Cardiex's mission remains focused on advancing medical technology for vascular health, with a strategic focus on expanding its product suite based on SphygmoCor® technology. The company's equity stood at AUD 5.6 million, reflecting strengthened financial positioning despite ongoing operational losses.
Key Points
  • Net loss for the year 2025 was AUD 13.23 million.
  • Revenue decreased significantly to AUD 3.55 million.
  • Cash used in operating activities increased to AUD 10.9 million.
  • Financing activities provided AUD 12.87 million.
  • Equity increased to AUD 5.6 million.
  • Focus on medical technology for vascular health.
  • No dividends were paid or proposed in 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.